The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
J. W. Neal
Research Funding - Genentech
R. Govindan
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly
Research Funding - Genentech
P. A. Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Genentech; Pfizer; Roche
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - Genzyme
T. L. Evans
No relevant relationships to disclose
D. B. Costa
Consultant or Advisory Role - Roche
R. P. G. Rosovsky
No relevant relationships to disclose
M. Lanuti
No relevant relationships to disclose
C. G. Azzoli
No relevant relationships to disclose
L. V. Sequist
No relevant relationships to disclose